Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial
Robert Bissonnette et al. Circ Cardiovasc Imaging. 2013.
Abstract
Background: Psoriasis is a chronic inflammatory disease associated with increased risks of myocardial infarction and stroke. Systemic treatments for moderate to severe psoriasis can reduce skin and joint inflammation; however, their effects on vascular inflammation are unknown.
Methods and results: This randomized, controlled trial included 30 patients with moderate to severe psoriasis and a history, or multiple risk factors, of coronary atherosclerosis. Patients were randomized (2:1) to receive either adalimumab subcutaneously for 4 months or to control nonsystemic treatment (topical therapies or phototherapy). Vascular inflammation was measured in the carotid artery and ascending aorta at baseline and week 15, by (18)F-fluorodeoxyglucose uptake on positron emission tomography. The change in target:
Background: =0.004) but not for the control group (-0.10 [95% CI, -0.32 to 0.12]; P=0.35). The difference between study arms for this primary end point did not reach statistical significance (-0.13 [95% CI, -0.01 to 0.14]; P=0.32). The change in target:
Background: =0.021) and in carotid arteries (-0.32±0.15, P=0.037) when analyzed separately (secondary end points). Changes in other positron emission tomography indices also improved significantly with adalimumab compared with controls in the ascending aorta and carotids. High-sensitivity C-reactive protein decreased by 51% at week 16 with adalimumab compared with 5% in controls (P=0·002).
Conclusions: The study did not meet its primary end point because the change in target:background ratio in patients randomized to adalimumab was not different from controls. Although adalimumab may reduce vascular inflammation in patients with moderate to severe psoriasis, this effect is not large enough to be demonstrated in a study with a small sample size.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00940862.
Similar articles
- Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM. Mehta NN, et al. Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394. doi: 10.1161/CIRCIMAGING.117.007394. Circ Cardiovasc Imaging. 2018. PMID: 29776990 Free PMC article. Clinical Trial. - TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.
Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, Maari C, Delorme I, Lynde CW, Tardif JC. Bissonnette R, et al. J Invest Dermatol. 2017 Aug;137(8):1638-1645. doi: 10.1016/j.jid.2017.02.977. Epub 2017 Mar 9. J Invest Dermatol. 2017. PMID: 28286061 Clinical Trial. - A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. Gordon KB, et al. N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646. N Engl J Med. 2015. PMID: 26154787 Clinical Trial. - Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab.
Di Costanzo L, Napolitano M, Patruno C, Cantelli M, Balato N. Di Costanzo L, et al. J Dermatolog Treat. 2014 Dec;25(6):489-94. doi: 10.3109/09546634.2013.848259. Epub 2013 Nov 12. J Dermatolog Treat. 2014. PMID: 24215490 Review. - The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know.
Kannan S, Heller MM, Lee ES, Koo JY. Kannan S, et al. J Dermatolog Treat. 2013 Apr;24(2):148-52. doi: 10.3109/09546634.2011.619159. Epub 2011 Sep 30. J Dermatolog Treat. 2013. PMID: 21888569 Review.
Cited by
- Structural and functional imaging of psoriasis for severity assessment and quantitative monitoring of treatment response using high-resolution optoacoustic imaging.
Li X, Yew YW, Vinod Ram K, Oon HH, Thng STG, Dinish US, Olivo M. Li X, et al. Photoacoustics. 2024 Apr 23;38:100611. doi: 10.1016/j.pacs.2024.100611. eCollection 2024 Aug. Photoacoustics. 2024. PMID: 38764522 Free PMC article. - Does Systemic Anti-Psoriatic Treatment Impact the Risk of Cardiovascular Disease? A Review Over Cardiovascular Imaging Studies.
Kaiser H, Näslund-Koch C, Kvist-Hansen A, Skov L. Kaiser H, et al. Dermatol Ther (Heidelb). 2024 Feb;14(2):303-321. doi: 10.1007/s13555-024-01098-z. Epub 2024 Jan 30. Dermatol Ther (Heidelb). 2024. PMID: 38291285 Free PMC article. Review. - A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy.
Dinc R. Dinc R. Transl Clin Pharmacol. 2023 Dec;31(4):191-201. doi: 10.12793/tcp.2023.31.e18. Epub 2023 Nov 22. Transl Clin Pharmacol. 2023. PMID: 38196998 Free PMC article. Review. - A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis.
Yu C, Huang Y, Yan W, Jiang X. Yu C, et al. Front Immunol. 2023 Oct 26;14:1272080. doi: 10.3389/fimmu.2023.1272080. eCollection 2023. Front Immunol. 2023. PMID: 37954610 Free PMC article. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials